Clinical and hemodynamic effects of an orally active endothelin-1-receptor antagonist in patients with refractory chronic heart failure.

被引：0
|
作者：
Suetsch, G
Christen, S
Yan, XW
Strobel, W
Rickenbacher, P
Hunziker, P
Bertel, O
Kiowski, W
机构：
[1] UNIV ZURICH HOSP,CH-8091 ZURICH,SWITZERLAND
[2] TRIEMLI HOSP,ZURICH,SWITZERLAND
[3] UNIV BASEL HOSP,CH-4031 BASEL,SWITZERLAND
来源：
CIRCULATION | 1997年 / 96卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：511 / 511
页数：2
相关论文
共 50 条
  • [21] Endothelin receptor antagonism in patients with chronic heart failure
    Love, MP
    Ferro, CJ
    Haynes, WG
    Plumpton, C
    Davenport, AP
    Webb, DJ
    McMurray, JJV
    CARDIOVASCULAR RESEARCH, 2000, 47 (01) : 166 - 172
  • [22] EFFECT OF GENETIC POLYMORPHISM ON THE CLINICAL RESPONSE TO MINERALOCORTICOID RECEPTOR ANTAGONIST THERAPY IN PATIENTS WITH HEART FAILURE.
    Sarhan, N.
    El Rouby, N. M.
    Solayman, M. H.
    Shahin, M. H.
    Langaee, T.
    Khorshid, H.
    El-Wakeel, L.
    Schaalan, M. F.
    Sabri, N. A.
    Cavallari, L. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S21 - S21
  • [23] PATHOPHYSIOLOGICAL ROLE OF ENDOTHELIN REVEALED BY THE 1ST ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST
    CLOZEL, M
    BREU, V
    BURRI, K
    CASSAL, JM
    FISCHLI, W
    GRAY, GA
    HIRTH, G
    LOFFLER, BM
    MULLER, M
    NEIDHART, W
    RAMUZ, H
    NATURE, 1993, 365 (6448) : 759 - 761
  • [24] EFFECT OF GENETIC POLYMORPHISM ON THE CLINICAL RESPONSE TO MINERALOCORTICOID RECEPTOR ANTAGONIST THERAPY IN PATIENTS WITH HEART FAILURE.
    Sarhan, N.
    El Rouby, N. M.
    Solayman, M. H.
    Shahin, M. H.
    Langaee, T.
    Khorshid, H.
    El-Wakeel, L.
    Schaalan, M. F.
    Sabri, N. A.
    Cavallari, L. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S69 - S70
  • [25] Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure -: The heart failure ETA receptor blockade trial (HEAT)
    Lüscher, TF
    Enseleit, F
    Pacher, R
    Mitrovic, V
    Schulze, MR
    Willenbrock, R
    Dietz, R
    Rousson, V
    Hürlimann, D
    Philipp, S
    Notter, T
    Noll, G
    Ruschitzka, F
    CIRCULATION, 2002, 106 (21) : 2666 - 2672
  • [26] Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure
    Berger, R
    Stanek, B
    Hülsmann, M
    Frey, B
    Heher, S
    Pacher, R
    Neunteufl, T
    CIRCULATION, 2001, 103 (07) : 981 - 986
  • [27] EFFECTS OF AN ORALLY ACTIVE VASOPRESSIN V(1)-RECEPTOR ANTAGONIST
    BURRELL, LM
    PHILLIPS, PA
    STEPHENSON, J
    RISVANIS, J
    HUTCHINS, AM
    JOHNSTON, CI
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1993, 20 (05) : 388 - 391
  • [28] Clinical and Hemodynamic Effects of Endothelin Receptor Antagonists in Patients With Heart Failure A Meta-Analysis of Randomized Controlled Trials
    Xiong, Bo
    Nie, Dan
    Cao, Yin
    Zou, Yanke
    Yao, Yuanqing
    Tan, Jie
    Qian, Jun
    Rong, Shunkang
    Wang, Chunbin
    Huang, Jing
    INTERNATIONAL HEART JOURNAL, 2017, 58 (03) : 400 - 408
  • [29] Effects of a specific endothelin-1A (ETA) receptor antagonist on the development of chronic heart failure (HF) in the dog.
    McConnell, PI
    Wang, W
    Gallagher, K
    Zucker, IH
    FASEB JOURNAL, 1996, 10 (03): : 2485 - 2485
  • [30] Rolofylline, an Adenosine A(sub 1)-Receptor Antagonist, in Acute Heart Failure.
    Massie, Barry M.
    O'Connor, Christopher M.
    Metra, Marco
    Ponikowski, Piotr
    Teerlink, John R.
    Cotter, Gad
    Weatherley, Beth Davison
    Cleland, John G. F.
    Givertz, Michael M.
    Voors, Adriaan A.
    DeLucca, Paul
    Mansoor, George A.
    Salerno, Christina M.
    Bloomfield, Daniel M.
    Dittrich, Howard C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (15): : 1419 - 1428
12345